Tilray/$TLRY

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Tilray

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mostly from alcohol.

Ticker

$TLRY
Sector
Primary listing

Employees

2,842

Headquarters

Leamington, Canada

Tilray Metrics

BasicAdvanced
$1.2B
-
-$2.46
1.95
-

What the Analysts think about Tilray

Analyst ratings (Buy, Hold, Sell) for Tilray stock.

Bulls say / Bears say

Tilray's international cannabis revenue jumped 71% in Q4 FY2025 and rose 19% for the year, driven by solid growth in Europe and supported by EU-GMP certified facilities in Germany and Portugal (GlobeNewswire).
Global cannabis gross margin improved by about 700 basis points to 40% in FY2025, reflecting Tilray’s effective product mix management and focus on higher-margin medical and vape offerings overseas (GlobeNewswire).
Tilray finished FY2025 with $256 million in cash and marketable securities, and repaid roughly $100 million in debt, lowering its net debt to adjusted EBITDA ratio to 0.3× and positioning itself for strategic investments (GlobeNewswire).
Tilray posted a GAAP net loss of $1.27 billion in Q4 FY2025, mainly due to a $1.40 billion non-cash impairment of goodwill and intangible assets, which overshadowed its actual operating performance (GlobeNewswire).
Net revenue for Q4 fell 2.3% year-over-year to $224.5 million, suggesting ongoing challenges in both cannabis and beverage divisions, impacted by SKU streamlining and export permit delays (Reuters).
Tilray’s industry continues to face pressure, with the valuation of leading cannabis companies—including Tilray—falling from a combined $37 billion in 2021 to only $4 billion in 2025, highlighting decreased investor confidence and stalled U.S. legalization efforts (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.

Tilray Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Tilray Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TLRY

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs